Despite other studies that have demonstrated that CXCL13 is elevated in many inflammatory CNS diseases and is not specific to NMO and MS, our findings show that therapy targeting CXCL13 may also be useful for NMO (Kothur, Wienholt, Brilot, & Dale, 2016). This evidence concerns the gene CXCL13 and neuromyelitis optica.